NCI-MATCH data confirm that these patients had tumors rich in molecular targets21 for which investigational agents are available, as follows: IDH1 mutations (17%), CDKN2A mutations (10%), BRAF mutations (7%), ERBB2 alterations (6%), NRAS mutations (6%), IDH2 mutations (5%), and FGFR2 alterations (3%), which segregated largely by site of origin of the cholangiocarcinoma. This evidence concerns the gene IDH2 and cholangiocarcinoma.